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ScienceDirectTable 1
Prevalence rates of psychotic symptoms in various patient
groups.
Disease/patient groups Prevalence rates
Bipolar disorder 76% psychotic symptoms
Schizophrenia 73% delusions, 59% hallucinations
Bordeline personality
disorder
50% psychotic symptoms
Lewy body dementia 25% delusions, 78% hallucinations
Parkinson’s disease 5% delusions, 30% hallucinations
Alzheimer’s disease 10% delusions, 21% hallucinations
Delirium 43% delusions, 86% hallucinations
Narcolepsy 2% delusions, 40% hallucinations
Anxiety disorder 27% psychotic symptoms
Post-traumatic stress
disorder
12% psychotic symptoms
Epilepsy 25% psychotic symptoms
Multiple sclerosis 7% delusions, 10% hallucinations
Reproduced from Sommer and Kahn RS (2014).Recent advances in the understanding of psychosis have
uncovered potential for a paradigm shift in related drug
discovery. The study of psychosis is evolving from its origins in
serendipity and empiricism to more formal, hypothesis driven
accounts of the cognitive substrates underlying hallucinations
and delusions. Recent evidence suggests that abnormal
salience and prediction error might underlie some forms of
psychosis. Such intermediate constructs could significantly
facilitate translational research. Salience and prediction error
can be assayed with simple tests of associative learning, and a
convincing back translation of effects, when combined with
measures of neurotransmitter release and brain activity could
for the first time allow robust, causal connections to be made
between molecular mechanisms in rodents and symptoms in
patients.
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Psychosis: a transdiagnostic term of variable
presentation
‘Psychosis’ presents contemporary researchers with a
conundrum. While the term is in widespread usage,
deeper analysis of its scientific application uncovers a
bewildering complexity of semantic heterogeneity. For-
mal constructions of the concept of psychosis emerged in
19th century psychiatry [1], and presently have their most
important homes as categorical definitions in DSM-V and
ICD-10 [2,3]. While there is no single, simple definition,
psychosis is generally understood as a clinical manifesta-
tion of an admixture of hallucinations (aberrant percep-
tions), delusions (false beliefs) and disorganised orCurrent Opinion in Behavioral Sciences 2015, 4:128–135 catatonic behaviour, often causing great distress to those
who experience it.
Psychotic experiences or ‘episodes’ are essentially trans-
diagnostic. Although most frequently associated with
conditions such as schizophrenia or bipolar disorder,
they can be present in many other situations, such as
Alzheimer’s disease, Parkinson’s disease, epilepsy, mul-
tiple sclerosis or even sleep disorders (Table 1). The
quality, pattern and impact of the components of a
psychotic episode can vary considerably between disease
states; where for instance psychosis in schizophrenia
most commonly presents as auditory hallucinations with
complex, persecutory delusions, that in Alzheimer’s
disease is more typically visual hallucinations with sim-
pler, ‘misidentification’-type delusions [4,5]. Moreover,
individual symptoms that characterise psychosis can
be clearly observed, on occasion, in the general popula-
tion [6]. The incidence of hallucinatory and delusional
experiences is far greater than the reported rates for
frank psychotic disorder, which has partly fuelled ongo-
ing research regarding the validity of the notion of
dichotomous presentation of psychosis (i.e., psychotic
or not-psychotic) versus that of a ‘continuum’ of psy-
chosis [7]. As it stands, the utility of a term like psycho-
sis for drug discovery, and the hypotheses that can be
effectively tested on the basis of this concept, are
somewhat limited.www.sciencedirect.com
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A number of the most important advances in the under-
standing of psychosis and its treatment have come from
serendipitous findings in schizophrenia research. Discov-
ery of the antipsychotic efficacy of chlorpromazine [8] and
clozapine [9] in the 1950s and 1970s, respectively, paved
the way for evolution of the so-called ‘dopamine hypoth-
esis’. Various lines of research now converge to strengthen
the validity of this hypothesis. Firstly, a large number of
currently prescribed antipsychotics have dopamine D2
receptor antagonist effects, where strong relationships
have been observed between D2 receptor occupancy
and clinical efficacy [10,11]. Overactivation of D2 recep-
tors is therefore likely to be one core chemical imbalance
that can predispose to psychosis. The involvement of
other receptors and pathways, such as the 5HT2A recep-
tor, in the efficacy of atypical neuroleptics should not be
overlooked, however [12]. Secondly, evidence from pro-
dromal patient studies, where dopamine receptor tracer
displacement is elevated in patients with ultra-high risk
(UHR) for psychosis or during first episode also supports
the central role of overactive striatal dopamine neuro-
transmission in the emergence of psychotic states [13,14].
Finally, drugs such as amphetamine, methamphetamine
and L-Dopa, which are known to increase dopamine
release or activate dopamine receptors, have also been
linked to the occurrence of psychotic episodes
[15,16,17]. Indeed, such molecules are often defined
as a class of ‘psychotomimetic’ agents. The dopamine
hypothesis is complemented by the ‘glutamate hypothe-
sis’ [18] which was also founded on initial serendipitous
findings of pharmacologically induced psychosis, in this
case following administration of phencyclidine and keta-
mine [19]. Both of these compounds have direct activity
at NMDA receptors and do affect glutamatergic neuro-
transmission. From a drug discovery perspective, nearly
all ‘antipsychotic’ research has been based on empirical
suppositions drawn from the dopamine and glutamate
hypotheses, where researchers have hoped that novel
agents can be identified if they share some of the proper-
ties that original antipsychotics possess in traditional
behavioural pharmacological tests of preclinical efficacy,
such as locomotor activity, prepulse inhibition or condi-
tioned avoidance responding [20,21]. Prima facie, such
assays appear to have little to do with psychosis as a
human would experience it, and there can be an uncom-
fortable circularity to such research efforts.
Recent drives to increase the translational validity of
psychiatric research in general may help to redefine the
concept of psychosis. The need for improved translational
validity has been borne from analysis of recent clinical
failures in neuropsychiatric drug discovery, where lack of
demonstration of target engagement and/or any measure
of efficacy has been a worryingly pervasive concern [22].
Consensus is now growing that older, categorical and
qualitative definitions of psychiatric disease need to bewww.sciencedirect.com superseded by more mechanistically plausible, and pref-
erably quantitative, domains of dimensional criteria as
expounded by the recent Research Domains Criteria
initiative [23]. Fractionating psychosis into more mech-
anistic subcomponents that could be back-translated into
rodents has great potential to increase construct validity
of animal research. It may also provide novel efficacy
biomarkers for human research allowing robust and un-
equivocal tests of hypotheses of cognitive enhancement,
which in turn would also improve predictive validity.
Translating aberrant salience and prediction
error between species
From a psychological viewpoint, evidence exists to sug-
gest that patients experiencing delusions may have pro-
blems with associative learning processes, exhibiting
biased reasoning (‘jumping to conclusions’), attentional
and attributional styles when ascribing meaning to events
[24]. However, many such constructs drawn from human
psychological literature are not necessarily easier to apply
preclinically than the symptoms-based constructs of psy-
chosis itself. A modern account of psychotic aetiology will
therefore attempt to reconcile top-down psychological
descriptions with bottom-up molecular hypotheses via
the study of intermediate constructs. Two constructs in
particular, aberrant salience and reward prediction error
(RPE) are gaining credence that they might represent
useful cognitive intermediates. The proposed mechanis-
tic chain would be that in an at-risk person dopaminergic
dysregulation results one or both of misattribution of
salience and inappropriate prediction errors, thereby lead-
ing to maladaptive learning [4,25,26]. Maladaptive
learning may in some cases alter a subject’s perception
and appraisal of the external world, manifesting in a
psychosis that has potential to be distressful and require
treatment intervention. The processes of aberrant sa-
lience and distorted prediction error may be mutually
reinforcing, a factor potentially contributing to the per-
sistence of delusional beliefs in psychosis.
While an unequivocal demonstration of a hallucinatory or
delusional event is beyond the realm of research in
rodents, measures of salience and prediction error can
be more readily employed and back-translated from clin-
ical findings. The first of these constructs, aberrant sa-
lience, simply refers to an inappropriate assignment of
potential importance, or value (or the lack thereof) to
stimuli, or events, in the environment [27]. The term
‘salience’ encompasses both low level stimulus-bound
properties, such as loudness, but also the informational
or motivational qualities that become attached to that
object. While dopamine function is more commonly
associated with reward and reinforcement, it is well
established that it also signals the occurrence of salient
novel events of potential significance [28–30]. These
responses are typically short-lived, particularly when
the event does not predict future reward or punishmentCurrent Opinion in Behavioral Sciences 2015, 4:128–135
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rent state. Aberrant salience potentially represents a
parsimonious construct through which hallucinatory
experiences can emerge, while also having the potential
to impact upon learning to cause delusional ideation. The
second construct, RPE, represents a core process by
which new information (both positive and negative) is
used to update predictions of future reward, a key com-
ponent of associative learning and thereby cognition
generally. Midbrain dopaminergic neuronal activity and
dopamine release in the ventral striatum correlates close-
ly with the RPE in temporal difference reinforcement
learning models [31–33]. It has been suggested that
delusions in psychosis might partly result from disrupted
RPE signalling, which in turn allow inappropriate
associations to form and then fail to be updated correctly
[34–36].
Despite there being a number of unresolved questions
and ongoing debates regarding the application and utility
of these constructs, pragmatic starting points now exist to
allow hypotheses related to drug discovery to be tested.
Of primary importance is the ability to establish homolo-
gous assays of aberrant salience and prediction error
between species. Both of these constructs can be readily
assessed via associative learning and reward-guided deci-
sion making paradigms. For instance aberrant salience
may be inferred from bias or abnormality in cue-reward
associations during operant learning tasks, particularly in
states of indefinite or ambiguous contingencies. Similarly,
positive and negative prediction error signals can be
readily generated with probabilistic cue discrimination
tasks. A crucial success factor here is that the final form of
these rodent and human assays should be homologous (as
far as possible), yet still have favourable practical attri-
butes for electrochemical and imaging studies as de-
scribed below.
With the establishment of homologous assays of salience
and prediction error across species, it then becomes
possible to consider the equivalence of underlying mech-
anisms and constructs between species. In this regard
there are now several fMRI studies of reward-based tasks
showing changes in RPE BOLD responses in patients
suffering from psychotic illness in the vicinity of the
midbrain dopamine cell bodies and regions that receive
strong dopamine input such as the ventral striatum [4,37–
39]. Until recently, it would have been difficult to realise
the non-human equivalents of these studies as the re-
straint or anaesthesia required for BOLD imaging would
have precluded the ability to meaningfully measure the
relevant parameters simultaneously. However, the in vivo
oxygen amperometry technique has been demonstrated
to represent a viable means of bridging this gap. This
technique allows real-time recording of brain tissue oxy-
gen concentrations in several regions simultaneously
while animals engage in behavioural tasks, includingCurrent Opinion in Behavioral Sciences 2015, 4:128–135 the types of reward-based learning and extinction para-
digms that would be required to probe aberrant salience
and prediction error [40].
Finally, a means to perturb baseline responses will also be
required to assess novel drug responses against. Psychoto-
mimetic drugs, such as methamphetamine, may allow a
translational means to provoke a homologous dopamine-
based disruption of aberrant salience and prediction error
between species. In this regard, it has demonstrated that a
single dose of methamphetamine in healthy volunteers
can induce mild psychotic symptoms whilst attenuating
ventral striatal and prefrontal BOLD signals [41].
Therefore, combining targeted pharmacological chal-
lenges [42] and electrochemical techniques, such as
fast-scan cyclic voltammetry to measure real-time dopa-
mine release [43], this brings forward the possibility of a
seamless translational test of a pharmacological hypothe-
sis at the level of a cognitive intermediate endpoint. The
simultaneous application of behavioural assays, electro-
chemical techniques and imaging paradigms thereby
offers a viable integrated cognitive approach by which
to robustly test how aspects of the dopamine hypothesis
relate to psychotic symptoms (Figure 1).
Using an integrated cognitive approach for
novel antipsychotic drug discovery
Although in its early stages, converging evidence suggests
that applying models linking dopaminergic neuronal ac-
tivity to learning and decision making can help shed light
on how dysfunction in this system might underlie the
development of psychotic symptoms.
Firstly, using such an integrated cognitive approach to
determine whether there is a pathological threshold for
the onset of full-blown psychosis could open novel
approaches to pharmacotherapy. Indeed, many otherwise
healthy individuals experience isolated psychotic events
that do not lead to long-term psychosis [7]. It is also been
reported that only a small subset of subjects with ultra-
high risk for psychosis (i.e., 20–40%) are ever likely to
proceed to a first episode of clinical psychosis [44]. Some
studies already suggest that levels of dopamine and
glutamate dysregulation may be sufficient to predict
transition to psychosis [45]. If dopamine imaging studies
can be related to dysregulation of salience and prediction
error processes, then assays of these cognitive constructs
may provide a very simple means to detect at-risk patients
before first break. The plausibility of a preventive treat-
ment intervention in psychosis ultimately depends on the
future availability of such diagnostic power that is also
relatively easy and cheap to administer. Future work
should test whether such individuals exhibit a form of
cognitive resilience, and/or the degree to which processes
of aberrant salience and prediction error are disturbed.
The finding that amphetamine administration can pro-
voke measurable differences in striatal dopamine releasewww.sciencedirect.com
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Figure 1
Electrochemistry and imaging tools
(e.g. dopamine voltammetry, oxygen amperometry)
DOPAMINE
FAST-SCAN CYCLIC
VOLTAMMETRY
TISSUE OXYGEN
AMPEROMETRY
Cognitive  tests
(e.g. probabilistic reward-b ased learning)
75%
25%
25%
75%
X
X
UNEXPECTED
REWARD
EXPECTED
REWARD
EXPECTED
REWARD
OMITTED
Dopamine activity and  RPE
in animals
REWARD
PREDICTION
ERROR (RPE)
SALIENT
NOVEL
STIMULUS
EF
FE
CT
 S
IZ
E
UNEXPECTED
REWARD
EXPECTED
REWARD
EXPECTED
REWARD
OMITTED
BOLD correlates of RPE in
animals and healthy  humans
R
PE
 E
FF
EC
T 
SI
ZE
PATIENTS/D-AMPHCONTROLS
BOLD correlates of RPE in
psychosis models and patients
HUMAN
BOLD fMRI
EXPECTED REWARD
= SMALL POSITIVE RPE
EXPECTED REWARD OMITTED
= LARGE NEGATIVE RPE
UNEXPECTED REWARD
= LARGE POSITIVE RPEHUMAN RODENT
CUES
EXPECTED LACK OF REWARD
= SMALL NEGATIVE RPE
O= O
Current Opinion in Behavioral Sciences 
An integrated and translational endpoint approach for relating dopamine dysfunction to psychosis via the use of intermediate cognitive constructs.
The top two panels illustrate example paradigms (top left) and neurochemical/imaging tools (top right) available in the translational toolkit.
Analogous probabilistic reward-based learning and decision making paradigms can be used in both human (e.g., [54,55]) and rodent studies.
Coupling these tasks with novel neurochemical techniques like fast-scan cyclic dopamine voltammetry and oxygen amperometry enables the
assessment of salience and reward prediction error signals in both normal animals and models of disease states with unprecedented temporal,
spatial and neurochemical specificity, and can allow direct translation with human neuroimaging studies in normal and disease states. The bottom
panels depict a schematic representation of the proposed integrated cognitive endpoint approach to psychosis. (1) How does dopamine function
modulate salience and reward prediction error? The use of fast-scan cyclic dopamine voltammetry in rodents during probabilistic reward-based
learning tasks allows for the measurement of dopamine cell outputs in response to novel stimulus presentation (salience) but also to expected and
unexpected reward delivery as well as omission or lack of expected reward (reward prediction error, RPE) (bottom left panel). (2) What are the
oxygen correlates of dopamine salience and RPE signals? Analogous RPE-like signals can be recorded in both rodents and humans using oxygen
amperometry and BOLD fMRI, respectively (middle panel). (3) Are these RPE-like oxygen correlates altered in psychotic patients and related
disease models? Such patterns of activation in response to RPEs can be used to allow indirect investigation of disrupted dopamine function in
patients with psychosis or normal subjects given a dose of D-amphetamine, as well as animal models of dopamine dysfunction (bottom right
panel).in schizotypal subjects offers an intriguing experimental
medicine model system for such research [46].
An integrated cognitive approach to psychosis may
also help to determine the extent to which different
forms of distressing psychotic experience share commonwww.sciencedirect.com mechanisms. A sensitised striatal dopaminergic system
is probably a necessary substrate for the emergence of
some forms of psychosis. However, it is not a sufficient
explanatory account in isolation. For instance, a subset
(i.e., 30–35%) of patients with schizophrenia show lim-
ited response to current dopamine-based antipsychoticCurrent Opinion in Behavioral Sciences 2015, 4:128–135
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associated with other distinct neurochemical abnormali-
ties, including prefrontal [49] and hippocampal gluta-
mate levels [50]. Future work using the approaches
described here to assess these different defined patient
groups may lead researchers to unify the dopamine and
glutamate hypotheses, where for instance an ‘upstream’
dysfunction in hippocampal glutamate function may
have a deleterious consequence on ‘downstream’ striatal
dopamine function [51,52] to impact on psychotic
symptoms.
The possibility of there being non-dopaminergic forms
of psychosis, and/or that psychosis in disease states
other than schizophrenia may be fundamentally mech-
anistically different is crucial for the design of future
clinical trials. Translational cognitive endpoints may
eventually allow for stratification of patient populations
based on defined, measurable constructs rather than on
superficial symptomatology. As an example of the po-
tential power of transdiagnosis, a recent imaging study
found reduced cue-elicited reward anticipation signalsFigure 2
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phrenia, alcohol dependence or major depressive disor-
der [53]. The converse may also be true, where studies
of this sort may potentially start to tease apart diagnostic
categories that appear to be related on the basis of face
validity. A future clinical trial in psychosis may there-
fore seem to recruit patients from a broad and superfi-
cially disparate range of disease states, yet may yield
greater efficacy through such targeting (Figure 2).
Finally, an integrated cognitive approach may help to
better define more effective antipsychotics with utility in
a broader range of psychoses. As described above, existing
antipsychotics were not developed with a cognitive
framework of psychosis in mind and have never been
fully studied in this context. The framework offered by
theories of aberrant salience and prediction error may
even help to explain some of the potential side effects
of D2 receptor antagonists. The sedation and social
detachment that can be observed following treatment
with typical antipsychotics in some patients might be
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Table 2
Outstanding issues.
 UHR patient literature would suggest elevated dopamine synthesis capacity in dorsal associative striatum, yet altered BOLD responses to reward
are usually reported in more ventral regions. Can these findings be unified?
 Given the different timescales over which dopamine operates, from phasic bursts of activity across a few tens of milliseconds to slower tonic
changes that may evolve across many minutes, can such temporal differences be related to specific aspects of salience or reward prediction error?
 Can changes in dopamine electrochemistry be unequivocally related to changes in oxygen amperometry and/or BOLD signal?
 If aberrant salience and prediction error are core substrates of psychosis, is there anything about the quality or magnitude of effect of change in
these processes that can predict a transition to a full-blown, distressing psychotic state?
 Should control subjects in clinical studies be assessed for incidence of subpathological psychotic behaviour, which may either reduce the
discriminant power of the study or be an interesting population to study per se?An integrated cognitive approach to psychosis may help
to titrate effects on salience/prediction error and there-
fore better control the beneficial versus adverse effects
of future therapies. Also, given the premise that cogni-
tive dysfunction might underlie psychosis, it is impor-
tant to consider how cognitive rehabilitation might be a
necessary prerequisite or co-therapy for any drug treat-
ment to be effective. Such combined clinical trials have
been relatively scarce to date, and may possibly explain
some recent failures of molecules, as seen particularly in
Phase III.
Contemporary psychosis research is entering an exciting
phase that ironically may lead to the term becoming
obsolete or dramatically redefined. Many researchers
are driven at present to better understand the causal
relationship between changes in BOLD signal observed
with fMRI and the underlying neurochemistry, and how
both may formally relate to maladaptive cognition ob-
served in psychosis (Table 2). It is here that the applica-
tion of electrochemistry to measure real time fluctuations
in both oxygen and dopamine signals in the striatum of
animals performing reward-guided learning and decision
making tasks, may be of particular use. There is hope that
via cognitive constructs, such as aberrant salience and
prediction error, basic molecular findings in animals can
be related to human dysfunction associated with psycho-
sis. This for the first time would then allow efficient use of
quantitative, translational hypothesis based research to
drive the development of much needed novel treatments.
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